This activity has been designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, students and researchers involved in the care of patients with CLL.
Statement of Need/Program Overview
The theme of the program, International Knowledge & Clinical Practice in 2022, reflects the collaboration to advance the research and treatment of patients with CLL globally. The content will reflect the most up-to-date clinical advancements in the CLL field.
After completing this activity, the participant should be better able to:
- Improving treatment of early stage CLL
- Understanding data from the most recent clinical trials
- Evaluating efficacy and toxicity of novel agents Understanding the role of the pathologist in CLL diagnosis
See link to Faculty
See link to agenda
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and MD Education Ltd. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
Medical Education Resources designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Reported Financial Relationship
Susan O’Brien (Chair)
Consultant: AbbVie, Alexion, Amgen, Aptose Biosciences Inc, Astellas, AstraZeneca, Autolus, Bristol Myers Squibb, Celgene, DynaMed, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, MEI Pharma Inc, Merck, NOVA Research Company, Pfizer, Pharmacyclics, TG Therapeutics, Vaniam Group LCC, Verastem, Vida Ventures
Research Support: Lacerta, Alliance, Beigene Ltd, Caribou Biosciences Inc, Gilead, Kite, Loxo Oncology Inc, Mustang, Nurix Therapeutics Inc, Pfizer, Pharmacyclics, Regeneron, TG Therapeutics
John Gribben (Chair)
Othman Al-Sawaf (January 2022)
Honoraria: Roche, Janssen, Gilead, AbbVie, AstraZeneca, Adaptive, BeiGene
Advisory Boards: AstraZeneca, Roche, Janssen, Gilead, AbbVie
Personal fees: Roche, Janssen, Gilead, AbbVie, AstraZeneca
Research grants: Beigene, Roche, Janssen, AbbVie
John Seymour (January 2022)
Advisory Boards: AbbVie, Acerta, Celgene, Genentech, Gilead, Janssen, Mei Pharma, Morphosys, Roche, Susesis, Takeda
Speakers’ Bureau: AbbVie, Celgene, Roche
Research Funding: AbbVie, Celgene, Janssen, Roche
Expert Testimony: Celgene, Roche
Jacqueline Barrientos (February 2022)
Advisory Boards: Beigene, AbbVie, Genentech
Research Support: AbbVie, Velosbio, Oncternal Therapeutics
Paolo Ghia (February 2022)
Advisory Boards: AbbVie, AstraZeneca, BMS, Jassen, Beigene, MSD, Roche, Sanofi
Research Recipient: AbbVie, AstraZeneca, BMS, Jassen
Honoraria: AbbVie, AstraZeneca, BMS, Jassen, Beigene, MSD, Roche, Sanofi
Ian Flinn (March 2022)
Consultancy: AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Gilead Sciences, Great Point Partners, Hutchison
MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Servier Pharmaceuticals, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, Yingli Pharmaceuticals
Research Grants: AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation Pharmaceuticals, Curis, CTI Biopharma, Fate Therapeutics, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, InnoCare Pharma, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Kite Pharma, Loxo, Merck, Millennium Pharmaceuticals, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem
Carol Moreno (March 2022)
John Gribben (April 2022 + Co Chair)
Honoraria: AbbVie, AstraZeneca, BMS/Celgene, Kite, Janssen, Morphosys, Novartis, Pharmacyclics, TG Therapeutics
Grant funding: NIHR, Wellcome Trust, Cancer Research UK, MRC, Janssen, AstraZeneca, Celgene/BMS
PI of clinical trials: AbbVie, BeiGene, Epizyme, Janssen, Kite/Gilead, Merck, MorphoSys, Pharmacyclics, Roche/Genentech, Takeda, TG Therapeutics
Jennifer Brown (April 2022)
Consultant: AbbVie, AstraZeneca, Acerta, BMS, Juno, Celgene, Catapult, Eli Lilly, Genentech, roche, Hutchmed, Janssen, MEI Pharma, Morphosys, AG, Novartis, Pfizer, Pharmacyclics, Rigel, Beigene.
Research Funding: Beigene, Gilead, Loxo Onc, Eli Lilly, SecurBio, Sun Pharma, TG Therapeutics.
Wojciech Jurczak (May 2022)
Advisory Boards: Janssen, Astra Zeneca, Loxo, Beigene. Meipharma
Research Funding: Abbvie, Astra Zeneca, Bayer, Beigene, Celgene,Gilead Sciences, Janssen, Loxo, Merck, Msd, Meipharma, Roche, Takeda, TgTherapeutics,
Jennifer Woyach (May 2022)
Research Support: AbbVie, Loxo Onc, Verastem, Kayropharm, Morphosys, Schrodinger.
Advisory Board: Brukinsa.
Consultant: AstraZeneca, Janssen, Pharmacyclics, Newave, Beigene, Genentech.
Debbie Stephens (June 2022)
Advisory Board: Karyopharm, TG Therapeutics
Research Funding: ACE
Stephan Stilgenbauer (June 2022)
Honoraria: Abbvie, Amgen, Celgene, Genentech, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Pharmacyclics.
Research Support: Abbvie, Amgen, Celgene, Genentech, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Pharmacyclics.
Speaker Fees: Abbvie, Amgen, Celgene, Genentech, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Pharmacyclics.
Travel Support: Abbvie, Amgen, Celgene, Genentech, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Pharmacyclics.
Carolyn Owen (August 2022)
Honoraria: AbbVie, AstraZeneca, Janssen
Arnon Kater (October 2022)
Davide Rossi (November 2022)
Honoraria: AbbVie, AstraZeneca, Janssen
Anna Schuh (December 2022)
Advisory Board: Roche, Janssen, Abbvie
Honoraria: Roche, AbbVie
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Content Manager||Reported Financial Relationship|
|MD Education Ltd.||No financial relationships to disclose|
|Planners at Medical Education Resources||No financial relationships to disclose|
Method of Participation
During the period January 2022 through December 2023, participants must 1) read the CME information such as the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Statements of credit will be issued after completion of each of the 12, monthly, activities.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, MD Education Ltd, and/or Genentech. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
There is no fee for this educational activity.
This programme has been supported by an educational grant from Genentech.
Medical Education Resources and MD Education Ltd. maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.
The only information MER obtains is information supplied voluntarily by the visitor.
We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.
We use the information to grade your posttest and to send you a certificate of completion of the activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.
For each activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the information to invite you to participate in other activities that we may offer.